Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Entrectinib

Generic name
Entrectinib
Brand name
ATC Code
L01EX14

Pharmacokinetics in children

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusion
  • Oral
    • 1 month up to 6 months
      • 250 mg/m²/day in 1 dose
    • ≥ 6 months
      • 300 mg/m²/day in 1 dose. Max: 600 mg/day.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The side effect profile in children is generally similar to the side effect profile in adults.

Adverse reactions that occurred more frequently in children compared to adults: ≥ 5% were neutropenia (19.8%), weight gain(18.7%), fractures (11%), lung infection (11%) and anemia (8.8%).

There were no differences in adverse events between children of different ages3 (infants, children up to 2 years of age, older children and adolescents).

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Anthracyclines and related substances
L01DB02
L01DB01
L01DB06
L01DB07
Other cytotoxic antibiotics
L01DC01
OTHER MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX06

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Reference

  1. Roche Registration G, SmPC Rozlytrek (EU/1/20/1460/001) Rev 9; 3-7-2024, www.ema.europa.eu

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes